Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
9.75
-0.04 (-0.41%)
Nov 21, 2024, 1:59 PM EST - Market open
Neumora Therapeutics Employees
Neumora Therapeutics had 124 employees as of December 31, 2023. The number of employees increased by 30 or 31.91% compared to the previous year.
Employees
124
Change (1Y)
30
Growth (1Y)
31.91%
Revenue / Employee
n/a
Profits / Employee
-$2,368,532
Market Cap
1.58B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124 | 30 | 31.91% |
Dec 31, 2022 | 94 | 6 | 6.82% |
Dec 31, 2021 | 88 | 35 | 66.04% |
Dec 31, 2020 | 53 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Certara | 1,391 |
10x Genomics | 1,259 |
GoodRx Holdings | 694 |
Clover Health Investments | 552 |
Immunocore Holdings | 497 |
Arvinas | 445 |
Dynavax Technologies | 408 |
Nurix Therapeutics | 284 |
NMRA News
- 8 days ago - This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho - Market Watch
- 9 days ago - Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - Neumora Therapeutics to Participate in Upcoming Conferences in November - GlobeNewsWire
- 3 months ago - Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - GlobeNewsWire
- 5 months ago - Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation - GlobeNewsWire
- 6 months ago - Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression - GlobeNewsWire
- 7 months ago - Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire